The company will evaluate the Hepzato kit as a combination therapy with the standard of care in patients with liver-dominant ...

Radium-223, enzalutamide, and a bone-protecting agent may be a new treatment option for mCRPC patients with bone metastases, according to Silke Gillessen, MD.

Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration (FDA) has ...

Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...

Truqap combination showed a statistically and clinically meaningful improvement in radiographic progression-free survival for ...